Stamford, Conn., March 09, 2023 – Avrio Health L.P., a subsidiary of Purdue Pharma L.P., has launched Senokot Kids Laxative* Gummies, a dietary supplement that provides safe, gentle overnight relief of occasional constipation for children ages 2 and up.
Senokot Kids Laxative* Gummies support the needs of children and their parents alike. Senokot Kids Laxative* Gummies are made with natural Senna extract, are free from many common food allergens and have a kid tested, great tasting flavor. The gummies do not contain high fructose corn syrup, artificial colors, sweeteners, parabens, polyethylene glycol or gelatin and are gluten-free and dairy-free.
The product will begin shipping this month.
*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
About Avrio Health L.P.
Avrio Health L.P., a subsidiary of Purdue Pharma L.P., is a consumer health products company that champions an improved quality of life for people in the United States through the reimagining of innovative product solutions. We have a strong portfolio of well-respected and proven effective brands, including Betadine®, Colace®, Senokot®, and SlowMag® Mg.
About Purdue Pharma L.P.
Purdue Pharma and its subsidiaries develop, manufacture and market medications and consumer health products to meet the evolving needs of healthcare professionals, patients, consumers and caregivers. If consummated, Purdue’s plan of reorganization will deliver billions in value to communities across the country to fund programs specifically for abatement of the opioid crisis. The bankruptcy settlement would also deliver funds to private abatement trusts for the benefit of personal injury claimants.
Substantially all of Purdue’s assets would be transferred to a new post-emergence company with a public-minded mission. This new company would be governed by new independent board members, and would operate in a responsible and sustainable manner taking into account long-term public health interests relating to the opioid crisis. The company would continue serving patients and consumers who rely on its medicines and products, pursuing its pipeline, and introducing medicines that will help save and improve lives. For more information, visit www.purduepharma.com.
Media Contact:
Michele Sharp
(203) 585-3195
news@pharma.com